Janux Therapeutics (JANX) Operating Income (2020 - 2026)

Janux Therapeutics (JANX) has 7 years of Operating Income data on file, last reported at -$34.2 million in Q1 2026.

• Operating Income for Q1 2026 came in at -$34.2 million, up 1.96% year-over-year; the trailing twelve-month figure through Mar 2026 was -$157.0 million (down 38.21% YoY), and the FY2025 annual result was -$157.7 million, down 59.51% from the prior year.
• Operating Income grew to -$34.2 million in Q1 2026 per JANX's latest filing, from -$42.4 million in the prior quarter.
• Over five years, Operating Income peaked at -$13.5 million in Q1 2022 and troughed at -$45.1 million in Q2 2025.
• A 5-year average of -$25.3 million and a median of -$20.3 million in 2023 frame the typical range for Operating Income.
• The sharpest annual moves came in 2022 and 2024: Operating Income tumbled 492.91% in 2022, then jumped 33.38% in 2024.
• A 5-year view of Operating Income shows it stood at -$18.3 million in 2022, then rose by 11.66% to -$16.1 million in 2023, then sank by 79.85% to -$29.0 million in 2024, then plunged by 46.1% to -$42.4 million in 2025, then grew by 19.31% to -$34.2 million in 2026.
• Business Quant data shows JANX's Operating Income at -$34.2 million in Q1 2026, -$42.4 million in Q4 2025, and -$35.3 million in Q3 2025.